NCT06774053 Swiss ProspectivE Cohort of TRAnsgender and Gender Diverse Individuals - The SPECTRA Study
| NCT ID | NCT06774053 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Transgender Individuals |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-04-20 |
| Primary Completion | 2046-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2026-04-20 with a primary completion date of 2046-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to understand the factors influencing the well-being and health of transgender and gender-diverse (TGD) individuals undergoing gender-affirming therapies in Switzerland. The study population includes TGD individuals aged 16 and older, at various stages of their medical transition, including those who have discontinued or detransitioned. The main question is: What are the key factors influencing the well-being and health outcomes of transgender and gender-diverse individuals undergoing gender-affirming therapies? Researchers will compare health outcomes across different subgroups, such as those at different stages of transition or detransition, to examine the effects of gender-affirming therapies. Participants will: Complete electronic questionnaires assessing gender congruence, quality of life, mental health, and other outcomes. Provide biological samples (e.g., blood, urine, stool, and skin swabs) for laboratory analysis. Undergo clinical evaluations related to endocrinology, fertility, dermatology, and urology as part of their routine follow-up.
Eligibility Criteria
Inclusion Criteria: * Age 16 years and above. * Established diagnosis of gender incongruence * Indication for gender affirming therapy or ongoing or discontinued gender affirming therapy Exclusion Criteria: * Unable to give informed consent * Missing commitment or ability to study protocol adherence
Contact & Investigator
Bettina Winzeler, PD Dr.
PRINCIPAL INVESTIGATOR
University Hospital Basel, Department of Endocrinology
Frequently Asked Questions
Who can join the NCT06774053 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, studying Transgender Individuals. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06774053 currently recruiting?
Yes, NCT06774053 is actively recruiting participants. Contact the research team at bettina.winzeler@usb.ch for enrollment information.
Where is the NCT06774053 trial being conducted?
This trial is being conducted at Basel, Switzerland, Lucerne, Switzerland, Zurich, Switzerland.
Who is sponsoring the NCT06774053 clinical trial?
NCT06774053 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Bettina Winzeler, PD Dr. at University Hospital Basel, Department of Endocrinology. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.